| Name | Title | Contact Details |
|---|
Ampio is an innovative drug discovery and development company combining scientific, regulatory, and business capabilities to efficiently develop a robust portfolio of novel therapeutic candidates. These therapeutic candidates, if approved, will address significant inflammatory conditions for which limited treatment options exist. Ampio’s therapeutic product pipeline has been developed through more than two decades of study at leading hospital-based research centers. Rigorous preclinical and clinical research efforts have yielded a diverse portfolio of late-stage product candidates focusing on the world’s most prevalent inflammatory conditions including osteoarthritis and diabetic macular edema. Significant discoveries in both basic science and clinical research have resulted in Ampio receiving over 180 patents throughout the world, with hundreds more pending. Further, hundreds of peer-reviewed publications, abstracts, and scientific presentations highlight the depth of research supporting Ampio’s therapeutic product candidates. Ampio’s leading product candidates are Ampion™ and Optina™. The company is currently conducting the second pivotal clinical trial in the US for Ampion, a biologic intra-articular injection being studied for the treatment of osteoarthritis of the knee. Ampio is also conducting a late-stage US clinical trial for Optina, an oral agent being studied for the treatment of diabetic macular edema. Millions of patients worldwide are affected by these conditions, for which limited treatment options exist. At Ampio, we strive to offer compelling therapeutic options for the patients most in need of new treatments, and we operate every day to advance our products’ development and make these available to patients.
FamilyPet.com provides great value to both pet businesses and pet owners across North America. With a multitude of brands and advertising models, FamilyPet.com has emerged as a leading online marketing tool for the pet industry. FamilyPet.com focuses on providing a resourceful and convenient destination for pet owners looking for high quality pet care services, products and insurance, along with providing educational information regarding the pet industry as a whole.
Roundtrip is the leading digital transportation marketplace for better health outcomes. We provide a simple, comprehensive patient ride ordering software that makes available a community of ride providers who complete the transport. The company is leading the industry in reducing patient no-shows through improved ride management. Roundtrip is built for healthcare professionals — care coordinators, social workers, nurses and other transport requestors —and offers easy-to-use online and mobile platforms that connect patients with non-emergency medical transportation (NEMT). Roundtrip is a comprehensive solution which supports all levels of transport: medical cars, wheelchair vans, stretcher vehicles, ALS/BLS, all payors, and all trips delivered when and where they are needed. Roundtrip is doing more than expanding access to care; we are changing how people manage their health in their everyday lives. As we address social determinants of health and aging in place, Roundtrip is driven to deliver engaged and empowered transportation experiences for our riders.
CGHN has been a trusted partner for Central Georgia independent physicians for over 20 years, with proven success in favorable payouts, dividends and contracting. This commitment to physician independence is at the very heart of CGHN`s identity. CGHN`s ownership structure ensures independent physicians in Central Georgia maintain a strong, controlling governance voice. CGHN is a growing, clinically-integrated network representing nearly 1,000 independent physicians, healthcare professionals and hospital partners across Central Georgia. Our goal is to deliver the best patient care experiences, while enhancing care quality and lowering costs.
MBF Healthcare Partners is a Miami, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.